Canopy Growth and Constellation Brands: Understanding the Warrants

You are receiving this as part of your subscription to Cannabis Profits Daily. To remove your email from this list, unsubscribe here. Saturday, August 31, 2019 The Warrant Situation between Canopy Growth and Constellation Brands By Greg Miller The latest earnings report from Canopy Growth Corp. (NYSE: CGC) did not inspire confidence. It wasn't as bad as most people believed, but there were some issues that could have been addressed better. There were some strategic mishaps, and executives running the show could have taken more responsibility for what went wrong. In fact, one of our members had a comment about that. Aimee S. said: "Growing pains for companies like Canopy are not unusual. What bothers me is that it did not take responsibility for its mistake and, from what you said, it's unclear if Canopy has adjusted its strategy." Aimee, you just said exactly what I told Canopy's investor relations staff after their call. The good news is that the company has adjusted its strategy - in addition to taking a reserve for returns, Canopy shipped very little oil or gel-cap product during the quarter that just finished so that stores could run down their inventories. The bad news is that on the earnings call, the executives made it seem like a pretty serious marketing error was just one of those things that happens from time-to-time. I communicated our shared concern to Canopy's management. I also received a question about Constellation Brands' investment in Canopy that I want to address right now... Monday at Midnight: You're Either In or You're Out This man's secret strategy for quick cannabis cash delivered his readers a cool 73%+ in under thirty days... and that's only one of the many recommendations he has to offer in this market. But it's not too late if you haven't joined him - you can get in before his next potentially double-, triple-, or quadruple-digit win... but after Monday, the price is going up. Because of an overwhelming response to his methods, we have to up the price to keep the ranks small. So if you're ready to join this investing revolution, find all the details here. WATCH When word got out about CBD's amazing health benefits, everything changed. With its remarkable ability to relieve chronic pain, treat anxiety and depression, and even reduce epileptic seizures, the market soared - practically overnight. And with 22% of consumers reporting that they use CBD to completely replace their over-the-counter and prescription drugs, the pharmaceutical industry is shaking in its boots... and with good reason. By 2022, experts believe that CBD sales will be up 3,622% - turning it into a $22 billion market. If you're ready to get started with this skyrocketing sector, we've got all the information right here. JOIN NOW You are receiving this e-mail at its028@gmail.com, as a part of your subscription to Cannabis Profits Daily. Remove your email from this list: Unsubscribe © 2019 The National Institute for Cannabis Investors All Rights Reserved The National Institute for Cannabis Investors | 1125 N Charles Street | Baltimore, MD 21201 Toll Free: 866.260.0361; International: 410.777.8270 Contact Customer Service Website: https://nicinvestors.com Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This information may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The National Institute for Cannabis Investors, 1125 N Charles Street, Baltimore, MD 21201. Privacy Policy | Terms & Conditions